Anveta Therapeutics is a drug discovery and early clinical development company dedicated to translating innovative academic science into differentiated small-molecule therapeutics. We collaborate closely with academic and institutional partners in India and globally to identify and advance novel targets and mechanisms at early stages, with the potential for first-in-class or best-in-class differentiation.

Our co-development model emphasizes scientific continuity, enabling originating researchers to remain actively engaged as programs advance from discovery through IND-enabling studies and early clinical development.

Anveta Therapeutics emphasizes hypothesis-driven medicinal chemistry, rigorous target validation, and early assessment of pharmacokinetics, safety, and biomarkers to enable disciplined execution and early risk reduction. Development decisions are guided by data quality, clear translational hypotheses, and well-defined clinical endpoints. Our primary value inflection points are IND filing and early clinical proof-of-concept. We maintain flexibility to pursue a range of downstream partnering options, including licensing or co-development, based on program maturity and strategic alignment.